A fentanyl vaccine developed at the University of Houston is set to enter clinical trials in mid-2025, aiming to prevent the opioid from reaching the brain.

A Phase II trial of toripalimab shows an overall response rate of 21.4% in advanced solid tumors with polymerase epsilon (POLE) or POLD1 mutations.

A randomized clinical trial reveals that adding interventions like intubation or turbinate fracture to conventional probing does not significantly improve the success rate of simple Congenital Nasolacrimal Duct Obstruction (CNLDO) resolution in children aged 12-24 months.

Clinical Accelerator collaborates with Tau Medical to conduct an Early Feasibility Study (EFS) of the 'Pivot Extend' device for tricuspid regurgitation (TR).

Loyal is conducting a clinical trial for an experimental drug designed to slow down the aging process in dogs, potentially extending their lives.

Bill Gates expressed optimism about the M72 tuberculosis vaccine clinical trial, anticipating a 70% efficacy in reducing the disease.

Brain+ has commenced a clinical trial to evaluate BrainBlossom, a next-generation cognitive training technology, for individuals with Mild Cognitive Impairment (MCI).

A clinical trial is underway to investigate the mechanisms behind diabetes and obesity in individuals with spinal cord injuries.

Ocuphire Pharma has dosed the first patient in its Phase 3 VEGA-3 clinical trial evaluating phentolamine ophthalmic solution 0.75% for presbyopia.

New cell-free DNA assays are improving minimal residual disease (MRD) detection in lymphoma, extending utility across various subtypes.

A meta-analysis of 12 trials reveals that donor human milk (DHM) significantly reduces the risk of necrotizing enterocolitis (NEC) in very preterm or very low-birth-weight (VLBW) infants.

A recent study investigates the association between branched-chain amino acids (BCAAs), particularly leucine, and clinical outcomes in patients at nutritional risk.

A Phase II clinical trial evaluated the combination of ASC22, an anti-PD-L1 antibody, and chidamide, a histone deacetylase inhibitor, in HIV-infected adults on ART.

Interim results from the NeoCOAST-2 Phase 2 trial show monalizumab, combined with durvalumab and chemotherapy, demonstrates encouraging clinical outcomes in early-stage NSCLC.

AbbVie presented data on mirvetuximab soravtansine for platinum-sensitive ovarian cancer, showing a 51.9% objective response rate in pre-treated patients.

• Researchers have identified a specific signature of vaginal bacteria and inflammatory proteins associated with elevated HIV infection risk in women. • The study pinpointed 14 bacterial taxa and six inflammatory proteins, where the presence of all markers significantly increased HIV risk. • _Lactobacillus crispatus_ was identified as a bacterial species associated with protection against HIV infection, offering potential preventative strategies. • Findings suggest potential for targeted interventions, such as antibiotics or probiotics, to modify the vaginal microbiome and reduce HIV risk.

The FDA supports using the α-synuclein seed amplification assay (αSyn-SAA) biomarker in clinical trials for Parkinson's disease and related conditions, potentially accelerating drug development.

Novo Nordisk's oral amycretin demonstrated significant weight loss, up to 13.1% in 12 weeks, in an early-stage trial.

The FDA has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype.

Viridian Therapeutics' veligrotug met primary and secondary endpoints in the THRIVE phase 3 trial for active thyroid eye disease (TED).